Last reviewed · How we verify
SHR-1316、Chemotherapeutic
SHR-1316 is a chemotherapeutic agent that inhibits tubulin polymerization to disrupt microtubule dynamics and induce cancer cell death.
SHR-1316 is a chemotherapeutic agent that inhibits tubulin polymerization to disrupt microtubule dynamics and induce cancer cell death. Used for Solid tumors (specific indications under phase 3 evaluation).
At a glance
| Generic name | SHR-1316、Chemotherapeutic |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Microtubule inhibitor |
| Target | Tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SHR-1316 is a microtubule-targeting chemotherapy that binds to tubulin and prevents microtubule assembly, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. This mechanism is typical of taxane or vinca alkaloid-class agents used across multiple solid tumor types.
Approved indications
- Solid tumors (specific indications under phase 3 evaluation)
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Nausea and vomiting
- Alopecia
Key clinical trials
- A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-1316、Chemotherapeutic CI brief — competitive landscape report
- SHR-1316、Chemotherapeutic updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI